



Updated Monthly

July 8, 2025

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:





Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

July 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Behavioral Science	2
Biomedical Research.....	2
Cancer	4
Cardiovascular and Pulmonary Health.....	5
Clinical Studies.....	6
Cognitive and Brain Health.....	6
Diagnostics	8
Endocrine & Metabolic Disease	8
Genomics	9
Health IT & Data.....	10
HIV/AIDS	10
Immunology & Infectious Disease	11
Medical Countermeasures.....	11
Mental Health.....	12
Musculoskeletal Health	13
NIH Common Fund.....	13
Pediatric Health.....	14

Regenerative Medicine.....	14
Small Business Development	15
Surgical Data Science.....	16
Therapeutics.....	16
Toxic Exposures	17

Recurring Opportunities

Advanced Research Projects Agency for Health	18
Air Force	19
BARDA	22
DARPA	22
Defense Threat Reduction Agency	22
Department of Energy.....	23
National Science Foundation	24
Navy	24
Office of the Undersecretary of Defense	25
Patient-Centered Outcomes Research Institute	25

GBG Acronyms	27
---------------------------	-----------





GBG Report

Updated Monthly

July 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

July 17, 2025 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or WVBio – your membership gets you access to the [private consultation meeting](#).

MHSRS 2025 – The MHSRS conference will be held on August 4-7 in Kissimmee, Florida. G2G will be there at Booth 419. [G2G hosted a webinar](#) where we shared insights on maximizing participation at the conference, plus pointers on engaging with government to foster collaborations and obtain funding! **If you are interested in G2G representing your company at this conference, please fill out this [form](#)!**

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BEHAVIORAL SCIENCE (1)		
1.	Forecast: Resource and Capacity Building to Advance the Science of Aggression across Species and Disciplines (R24 Clinical Trial Optional) (NIH/OBSSR) TEMP-31698	This NOFO will solicit applications to advance research on the mechanisms of aggressive behavior across species and disciplines. Aggressive behavior is associated with numerous chronic diseases, especially psychiatric and neurological conditions. Additional scientific resources and capacity are needed to accelerate and enhance research to address this public health challenge through improved mechanistic understanding, prevention, and treatment of aggressive behavior. https://www.grants.gov/search-results-detail/359820	Total funding of \$1.5 million	Estimated post date: 10/17/25 Estimated proposal date: 1/16/26
		BIOMEDICAL RESEARCH (6)		
2.	Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional) (NIH) FOR-EB-26-001	This is an opportunity for New and Early Stage Investigators to pursue research programs that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high-risk high-impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. https://www.grants.gov/search-results-detail/358886	TBD	Estimated post date: 11/21/25 Estimated proposal date: 2/16/26
3.	Forecast: Maximizing Investigators' Research Award (NIH/NIGMS) FOR-GM-27-002	The goal of MIRA is to increase the efficiency of NIGMS funding by providing investigators with greater funding stability and scientific flexibility, thereby enabling researchers to take on more ambitious and innovative studies, enhancing scientific productivity and the chances for important breakthroughs. https://www.grants.gov/search-results-detail/359862	TBD	Estimated post date: 11/3/25 Estimated proposal date: 1/27/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
4.	Forecast: Opportunities for Collaborative Research at the NIH Clinical Center (NIH) FOR-OD-25-407	The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). https://www.grants.gov/search-results-detail/359659	TBD	Estimated post date: 9/1/25 Estimated proposal date: 12/12/25
5.	CoasterChase (DoD/DARPA) HR001125S0014	The CoasterChase program aims to develop a multimodal, ingestible, sensing and stimulation platform for use in monitoring and modulating biomarkers of acute stress from within the small intestine. Proposed research should investigate innovative approaches that enable revolutionary advances in enteric neuromodulation and sensing, ingestible electronics, and modulation of the stress response. https://sam.gov/opp/82431f9c8fb14f73bfd8202a06391a03/view	Total funding of up to \$25 million	Abstract: 7/24/25 Proposal: 8/28/25
6.	Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional) (NIH) PAR-25-383	This NOFO supports investigators in pursuing translational activities and clinical studies to advance the development of therapeutic and diagnostic devices for disorders within the missions of the participating NIH institutes and centers, as well as the HEAL and BRAIN Initiatives. Activities supported by this NOFO include implementation of clinical prototype devices, non-clinical safety and effectiveness testing, design verification and validation activities. https://grants.nih.gov/grants/guide/pa-files/PAR-25-383.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/28/28
7.	NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed) (NIH/NIGMS) PAR-25-416	This NOFO encourages applications for support of resources that will provide access to state-of-the-art equipment, technologies, research tools, materials, organisms, software, and/or services to a substantial regional (multi-state) or national user base. https://grants.nih.gov/grants/guide/pa-files/PAR-25-416.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 6/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER (10)		
8.	<p>Forecast: Early Stage Development; Advanced Development of; and Sustained Support for Informatics Technologies for Cancer Research and Management (U01/U24 Clinical Trial Optional) (NIH/NCI)</p> <p>FOR-CA-25-073 (U01) FOR-CA-25-074 (U24) FOR-CA-25-075 (U24)</p>	<p>These NOFOs will solicit applications for the development and advanced development and enhancement of emerging informatics technologies; and the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.</p> <p>https://www.grants.gov/search-results-detail/359892 (U01) https://www.grants.gov/search-results-detail/359855 (U24) https://www.grants.gov/search-results-detail/359853 (U24)</p>	TBD	<p>Estimated post date: 8/29/25 Estimated proposal date: 11/21/25</p>
9.	<p>Forecast: Research Opportunities in Cancer Epidemiology Cohort Studies; and Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) (NIH/NCI)</p> <p>FOR-CA-25-076 FOR-CA-25-077</p>	<p>These NOFOs support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship; and support the establishment of the next generation of cancer epidemiology cohorts.</p> <p>https://www.grants.gov/search-results-detail/359091 https://www.grants.gov/search-results-detail/359090</p>	TBD	<p>Estimated post date: 8/1/25 Estimated proposal date: 11/5/25</p>
10.	<p>Forecast: The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) (NIH/NCI)</p> <p>FOR-CA-25-085</p>	<p>This NOFO will solicit applications for research on use integrative systems-level approaches to address a specific question in metastasis research. Such projects are expected to integrate with the NCI's Metastasis Research Network (MetNet) and complement its ongoing research. Proposed projects should emphasize one of the central themes defined in the MetNet NOFO (RFA-CA-20-029) such as dormancy, early dissemination, cellular and/or physical microenvironment crosstalk, or mechanisms of responses by metastatic cells to therapies.</p> <p>https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-20-029.html https://www.grants.gov/search-results-detail/359725</p>	TBD	<p>Estimated post date: 8/22/25 Estimated proposal date: 10/22/25</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
11.	Forecast: The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed) (NIH/NCI) FOR-CA-25-090	The PK Laboratory will organize biospecimen collections and provide subsequent analyzes of pharmacokinetic endpoints, drug-drug interactions, cytochrome P450 (CYP) interactions, pharmacodynamics, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratory is to advance the clinical development of NCI IND agents by providing a comprehensive understanding of pharmacokinetic behavior of these agents under study in ETCTN trials. https://www.grants.gov/search-results-detail/359854	Total funding of \$850,000	Estimated post date: 7/31/25 Estimated proposal date: 10/30/25
12.	FY25 Breast Cancer Research Program (BCRP) (DoD/CDMRP) HT942525BCRPCREA (CREA) HT942525BCRPBTA12 (BTA12) HT942525BCRPBTA3 (BTA3) HT942525BCRPEOHS (EOHSA)	The BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. Three award mechanisms have been posted, in four NOFOs: Breakthrough Award 1-2 and 3; Era of Hope Scholar Award; and Clinical Research Extension Award. Applications submitted to the FY25 BCRP must address one or more of the Overarching Challenges. https://cdmrp.health.mil/bcrp/default https://cdmrp.health.mil/funding/bcrp	Up to \$6 million, for up to 4 years Dependent upon proposal and award mechanism	Pre-Application: 6/13/25 Proposal: 6/27/25 (BTA12/CREA/E OHSA) Pre-Application: 6/13/25 Proposal: 9/10/25 (BTA3)
13.	Forecast: Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not Allowed) (NIH/NCI) NOT-CA-25-104	The purpose of CISNET is to use simulation modeling to extend evidence provided by trial, epidemiologic, and surveillance data to guide public health research and priorities across the cancer continuum. https://www.grants.gov/search-results-detail/359729	TBD	Estimated post date: 7/31/25 Estimated proposal date: 11/7/25
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
14.	Forecast: Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (NIH/NHLBI) FOR-HL-25-020	This NOFO will solicit applications for research on expanding the scope of an international cardiac surgery research platform, which already includes interventional cardiology, and peri-operative care of cardiac patients. Other areas of HLBS research will be incorporated, including dissemination and implementation science, circadian medicine, and mechanistic science efforts. https://www.grants.gov/search-results-detail/359182	TBD	Estimated post date: 2/2/26 Estimated proposal date: 6/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
15.	Forecast: Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (NIH/NHLBI) FOR-HL-25-020	This NOFO will solicit applications for research on expanding the scope of an international cardiac surgery research platform, which already includes interventional cardiology, and peri-operative care of cardiac patients. Other areas of HLBS research will be incorporated, including dissemination and implementation science, circadian medicine, and mechanistic science efforts. https://www.grants.gov/search-results-detail/359182	TBD	Estimated post date: 2/2/26 Estimated proposal date: 6/1/26
		CLINICAL STUDIES (1)		
16.	Forecast: NIAID Clinical Trial Implementation Cooperative Agreement (NIH/NIAID) FOR-AI-27-007	This program encourages cooperative agreement applications for implementation of investigator-initiated, milestone driven, high-risk clinical trials including mechanistic studies associated with these clinical trials. Due to this focus, the program encompasses both basic and clinical research. This program includes support for the conduct, completion, and analysis of the clinical trial. https://www.grants.gov/search-results-detail/359859	TBD	Estimated post date: 12/5/25 Estimated proposal date: 2/25/26
		COGNITIVE AND BRAIN HEALTH (9)		
17.	Forecast: Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (NIH/NIA) FOR-RFA-AG-26-012	This NOFO will invite applications proposing a Data Coordinating Center that integrates and disseminates multiscale mouse brain datasets for the aging and AD research community. The Data Coordinating Center will establish the Aging and AD Mouse Brain Atlas (AD-MBA). The Data Coordinating Center will (1) leverage the NIA-supported AD Knowledge Portal data infrastructure to facilitate hosting, deposition, and dissemination of multimodal datasets generated by the AD-MAPs program, (2) facilitate collaborative analyses among the data-contributing teams, (3) develop/optimize and incorporate tools for multiscale integration of multi-omics and connectomics datasets, and (4) create a broadly accessible web-based interface for the visualization and dissemination of integrated multiscale data. https://www.grants.gov/search-results-detail/359740	TBD	Estimated post date: 9/1/25 Estimated proposal date: 1/25/26
18.	Forecast: Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (NIH/NIA) FOR-RFA-AG-26-019	This NOFO will invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. https://www.grants.gov/search-results-detail/359857	TBD	Estimated post date: 8/1/25 Estimated proposal date: 10/5/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
19.	Forecast: Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (NIH/NIA) FOR-RFA-AG-26-020	This NOFO will 1) invite applications that propose to develop and implement early-to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), and 2) stimulate studies to enhance trial design and methods. https://www.grants.gov/search-results-detail/359850	TBD	Estimated post date: 8/1/25 Estimated proposal date: 10/5/25
20.	Forecast: Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum (NIH/NIA) FOR-TEMP-25653	The overarching goal is to determine the occurrence of age-related neurodegeneration across the heterogeneities of the ASD spectrum, characterize the physiopathology and manifestation of AD/ADRD in ASD, and, ultimately, develop precision-medicine strategies tailored to this understudied population. It is expected that proposed studies pursue deep phenotyping of aging individuals across the ASD spectrum, along with the characterization/validation of existing biomarkers of age-related cognitive decline and/or dementia in this population, and/or the discovery of novel ones. https://www.grants.gov/search-results-detail/359851	TBD	Estimated post date: 12/1/25 Estimated proposal date: 2/5/26
21.	National Alzheimer's Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-26-003	A National Alzheimer's Coordinating Center (NACC) is to serve NIA as: 1) a national data resource, collecting data from the ADRCs and their affiliated data and sample repositories; 2) a facilitator of current and future research on AD/ADRD; and 3) the central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-003.html	Up to \$10.35 million per year, for 5 years	Letter of intent: 9/16/25 Proposal: 10/17/25
22.	Forecast: Artificial Intelligence and Technology Collaboratory (NIH/NIA) RFA-AG-26-006	Goals of the AITC Program are as follows: (1) serve as a national resource to promote development and implementation of innovative AI and technology approaches to advance aging and AD/ADRD priorities; (2) support nationwide research projects to develop and implement AI and technology approaches and respond rapidly to emerging priorities in the shifting AI and technology landscape; and, (3) collaborate with a wide range of stakeholders in addressing algorithmic fairness and how to incorporate AI and technology approaches in the special circumstances of individuals experiencing cognitive decline/impairment. https://www.grants.gov/search-results-detail/359654	TBD	Estimated post date: 8/15/25 Estimated proposal date: 10/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
23.	Forecast: Aging Mammalian Tissues In Vitro (NIH/NIA) RFA-AG-26-014	This NOFO will solicit applications that propose interdisciplinary research that aims to develop complex mammalian 3-dimensional (3D) in vitro microphysiological systems (MPS) to model aging and recapitulate aging processes/phenotypes observed in the whole organism in vivo. It is anticipated that the NOFO will primarily focus on human cell-derived MPS (e.g., tissue chip, organ-on-chip, tissue organoids). However, systems developed using cells of nonhuman mammalian origin may be acceptable for benchmarking, system validation, or when their relevance to understanding human aging biology is justified. https://www.grants.gov/search-results-detail/359723	TBD	Estimated post date: 8/15/25 Estimated proposal date: 10/15/25
24.	Cure One, Cure Many Award in Neuroinflammation (ABF)	The American Brain Foundation seeks interdisciplinary proposals that identify novel inflammation-based mechanisms, pathways, biomarkers, therapies, and/or technologies that have potential to produce significant clinical advances in neurodegenerative, developmental, autoimmune, inflammatory, or neuromuscular diseases. These grants support high-risk, high reward and translational research with a focus on clinical impact. https://www.americanbrainfoundation.org/for-researchers/#cocm	Up to \$1 million per year, for up to 2 years Dependent upon award mechanism	Pre-proposals due 7/15/25 Invited proposals: 9/30/25
		DIAGNOSTICS (1)		
25.	Biothreat Diagnostic Rapid Response (BARDA/RRPV) RPP-25-06-DxR2	The DxR2 program will solicit new point of care/remote-use products with domestic manufacturing capabilities which address test development for Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) biothreats to include glanders, botulism, tularemia, typhus, smallpox, and plague. The overall goals of this program are to build a biothreat diagnostic portfolio, maintain domestic test manufacturing facilities, and to enable just-in-time manufacturing practices to be able to rapidly produce biothreat tests and needed supplies at scale, and to achieve aggressive test delivery schedules. https://www.rpv.org/solicitation/biothreat-diagnostic-rapid-response/	Up to \$10 million, for 3 years	Proposal: 8/4/25
		ENDOCRINE & METABOLIC DISEASE (6)		
26.	Kidney Precision Medicine Project: Recruitment Sites, Tissue Interrogation Sites, and Central Hub (NIH/NIDDK) NOT-DK-26-301 NOT-DK-26-302 NOT-DK-26-303	These NOFOs will allow the KPMP to (1) honor its commitment to existing enrollees (~500) by continuing robust longitudinal clinical follow-up, (2) achieve additional power by enrolling new participants (>500) for in-depth molecular interrogation and follow-up, and (3) accelerate the discovery and validation of novel pathways, targets, and disease subgroups by directly supporting the efforts of the broader research community to fully leverage KPMP data. https://www.grants.gov/search-results-detail/359198 https://www.grants.gov/search-results-detail/359199 https://www.grants.gov/search-results-detail/359197	Total funding of \$15 million	Estimated post date: 7/5/26 Estimated proposal date: 10/5/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE		
27.	Forecast: Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (NIH/NIDDK) NOT-DK-26-306	This NOFO will solicit applications for research on understanding how to engineer inherent characteristics of stem cell-derived islet cell products that can result in improved cell replacement therapy outcomes. It will aim to stimulate studies on targets and pathways amenable to such engineering approaches and to encourage preclinical testing and validation of such strategies. https://www.grants.gov/search-results-detail/359016	Total funding of \$3 million	Estimated post date: 8/1/25 Estimated proposal date: 10/1/25
28.	Forecast: New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (NIH/NIDDK) NOT-DK-26-307	This NOFO will solicit applications for research to overcome barriers that limit progress toward more effective open- and closed-loop diabetes control systems. This may include research that addresses: 1) innovation of sensing relevant analytes/physiologic signals; 2) novel formulation and delivery of hormones; 3) artificial intelligence (AI)/machine learning (ML)-driven tools/algorithms; and 4) digital twin modeling to augment decision support and automated control systems with the goal of improving glycemic control, reducing burden of care, and enhancing quality of life of people with T1D. https://www.grants.gov/search-results-detail/359200	Total funding of \$3 million	Estimated post date: 9/1/25 Estimated proposal date: 10/1/25
29.	Forecast: The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional) (AMP) NOT-DK-26-313	The overarching goal of AMP CMD is to use human genetics as a powerful approach to obtain human-data derived disease understanding and biomarker/therapeutic opportunities. This is being accomplished through systematic aggregation of existing genotype-phenotype data for CMD, related traits, and its complications as well as the generation of a large amount of new omic data. The goal of the NIDDK-funded component of the consortium is to aid in advancing the understanding of the mechanisms responsible for T2D development through the integration of large-scale genetic data that will contribute to further deconstruction of the pathophysiology of T2D, and potentially of its major complications, including macrovascular and microvascular disease. https://www.grants.gov/search-results-detail/359015	Total funding of \$3 million	Estimated post date: 10/1/25 Estimated proposal date: 3/1/26
		GENOMICS (1)		
30.	Forecast: ClinGen Genomic Curation Expert Panels (NIH) NOT-HD-25-006	This NOFO will solicit applications for the establishment and continuation of Genomic Curation Expert Panels that manually curate, review and define the clinical relevance of genes and variants as part of the NIH established and funded Clinical Genome Resource (ClinGen). https://www.grants.gov/search-results-detail/359827	Total funding of \$880,000	Estimated post date: 3/25/26 Estimated proposal date: 5/25/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (2)		
31.	Forecast: Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) (NIH Common Fund) NOT-RM-25-015	The goals of this NOFO are to 1) promote the use of Common Fund data sets by supporting pilot studies based on analyses across two or more Common Fund data sets with a special category of MoTrPAC only focused projects; 2) enhance the utility of existing Common Fund data sets by developing workflows, analytic and simulation tools which will enable simultaneous analysis of multiple Common Fund data sets; and 3) demonstrate the added-value of integrating multiple Common Fund data resources in addressing biomedical research questions. https://www.grants.gov/search-results-detail/359879	Total funding of \$4 million	Estimated post date: 9/19/25 Estimated proposal date: 11/19/25
32.	Unlocking Insights: Analyzing All of Us Data for Drug Addiction Research Challenge (NIH/NIDA)	The Challenge goal is to motivate teams of researchers to delve into the extensive dataset provided by the All of Us Research Program, with the goal of uncovering insights and advancing research into all aspects of substance use, misuse, and drug addiction. Researchers are tasked with extracting relationships between the different variables in the All of Us dataset and describing how various factors, such as social, genetic, lifestyle, behavioral, biological, and others, contribute to substance use, misuse, and drug addiction susceptibility, relapse, course, and outcomes. https://www.challenge.gov/?challenge=nida-all-of-us-data-challenge	Up to \$20,000	Proposal: 9/8/25
		HIV/AIDS (2)		
33.	Forecast: Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) (NIH/NIAID) FOR-AI-27-017	This program will focus on: elucidating mechanisms of persistence and pathogenesis; discovering and developing clinically relevant biomarkers; discovering and/or validating host and/or new viral drug targets; and developing non-invasive diagnostics. https://www.grants.gov/search-results-detail/359860	Total funding of \$8 million	Estimated post date: 5/21/26 Estimated proposal date: 8/19/26
34.	Forecast: HIV Pediatric, Adolescent and Maternal Clinical Trials (NIH/NICHD) NOT-HD-25-007	This NOFO will solicit applications for research focused on high-priority HIV studies for infants, children, youth and young adults (AYA), and maternal populations. An HIV clinical trials network focused exclusively on pediatric and maternal populations will innovate and conduct rigorously designed, collaborative clinical trials in partnership with site consortia to address high-priority research areas in HIV and related comorbidities and coinfections. https://www.grants.gov/search-results-detail/358992	Total funding of \$30 million	Estimated post date: 11/21/25 Estimated proposal date: 3/25/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (3)		
35.	Forecast: NIAID Clinical Trial Implementation Cooperative Agreement (NIH/NIAID) FOR-AI-27-007	This program encourages cooperative agreement applications for implementation of investigator-initiated, milestone driven, high-risk clinical trials including mechanistic studies associated with these clinical trials. Due to this focus, the program encompasses both basic and clinical research. https://www.grants.gov/search-results-detail/359859	TBD	Estimated post date: 12/5/25 Estimated proposal date: 2/25/26
36.	Forecast: NIAID Investigator Initiated Program Project Applications (NIH/NIAID) FOR-AI-27-008	The program encourages applications for investigator-initiated program projects proposed in scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes; mechanisms regulating immune system development and function across the lifespan, and/or in response to infectious pathogens; immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. https://www.grants.gov/search-results-detail/359732	TBD	Estimated post date: 12/12/25 Estimated proposal date: 1/25/26
37.	Forecast: NIAID Resource-Related Research Projects (NIH/NIAID) FOR-AI-27-009	This program encourages applications for investigator-initiated research projects that will develop resources to serve biomedical research. The resource should be available to any qualified investigator, and should be highly quality controlled, replenishable, and not duplicate resources available commercially or through other sources. Proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, or transplant rejection, and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. https://www.grants.gov/search-results-detail/359692	TBD	Estimated post date: 11/26/25 Estimated proposal date: 1/26/26
		MEDICAL COUNTERMEASURES (4)		
38.	Upregulation of Endogenous Butyrylcholinesterase (BuChE) for Organophosphorus Nerve Agent (OPNA) Prophylaxis (UPREG) (MCDC/DTRA) RPP-25-05	DTRA's JSTO seeks to develop technologies that temporarily upregulate the expression of endogenous Butyrylcholinesterase (BuChE) and demonstrate enhanced protection against Organophosphorus Nerve Agent (OPNA) intoxication through submission of an Investigational New Drug (IND) filing with the FDA. Manufacturing needs to demonstrate the ability to provide sufficient material for conducting clinical trials. https://www.medcbn.org/business-opportunities/	TBD; must be MCDC member to apply	Enhanced white paper: 7/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES		
39.	Operationalizing Novel Technologies for Advanced Rapid Generation of Effective Medical Countermeasures (MCM) (ONTARGET) (MCDC/DTRA) RPP-25-06	This project seeks to identify and evaluate promising technologies for Department of Defense (DoD) use. Staying ahead of an evolving threat landscape requires incorporating novel approaches to ensure a robust, agile, and efficient MCM development pipeline. Technologies of interest are those aimed at significantly enhancing MCM performance, accelerating development timelines, and improving success rate and speed of response to biological threats. https://www.medcbrn.org/business-opportunities/	TBD; must be MCDC member to apply	Enhanced white paper: 7/9/25
40.	Defined Rapid Antigen Identification and Immunogenic Characterization (DRAIIC) (MCDC/DTRA) RPP-25-07	This objective of this project is to identify current and developing technologies that can rapidly and accurately identify immunogenic regions of antigens in novel and emerging pathogens. This effort will fulfill JSTO Chem Bio Medical (CBM) vaccine program requirements by developing technologies to rapidly and accurately identify antigenic components in emerging pathogens that elicit significant and persistent protective immunity, and which can be incorporated into current vaccine platform(s). https://www.medcbrn.org/business-opportunities/	TBD; must be MCDC member to apply	Enhanced white paper: 7/11/25
41.	Increased Micro Sampling to Monitor Immunological Response (IMMIR) (MCDC/DTRA) RPP-25-08	The current technology and animal use and care guidelines limit the number of blood samples that can be taken in the period between vaccine administration and the fully developed immunological response. The objective of this project is to identify and develop technologies that can expand the range of in vivo micro sampling to comprehensively assess the extended developmental immune response to vaccination. These nascent technologies are expected to allow increased or continuous in vivo micro sampling and in parallel utilize detection technologies that can characterize post-vaccination immune maturation in small samples. https://www.medcbrn.org/business-opportunities/	TBD; must be MCDC member to apply	Enhanced white paper: 7/11/25
		MENTAL HEALTH (2)		
42.	Forecast: Advancing Research on Empirically-Supported Interventions for Older Adults Living with Serious Mental Illness (SMI) (NIH/NIMH) FOR-MH-26-180	This NOFO will solicit applications for research focused on the optimization, delivery, sustainability, and effectiveness of empirically-supported interventions for addressing the mental health needs of older adults with serious mental illness (SMI). https://www.grants.gov/search-results-detail/359201	Total funding of \$3 million	Estimated post date: 8/15/25 Estimated proposal date: 10/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
43.	Forecast: Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents (NIH/NIMH) FOR-MH-26-185	This NOFO will solicit applications for research that addresses methodological challenges associated with clinical trials involving psychotomimetic agents (PMAs). PMAs, including classic psychedelics such as psilocybin, dissociative anesthetics such as ketamine, and entactogens such as 3,4-methylenedioxymethamphetamine (MDMA), have demonstrated promising benefits for the relief of depression, anxiety and other mental health disorders. The goal of this NOFO is to improve the understanding of the key components underlying the therapeutic effects of PMAs and thereby increase confidence in the results from clinical trials with PMA intervention(s). https://www.grants.gov/search-results-detail/359202	Total funding of \$5 million	Estimated post date: 9/3/25 Estimated proposal date: 11/3/25
		MUSCULOSKELETAL HEALTH (3)		
44.	Forecast: Ancillary Studies to Ongoing Clinical Projects (R01/R21 CT Not Allowed) (NIH/NIAMS) FOR-AR-25-006 (R01) FOR-AR-25-007 (R21)	These NOFOs will solicit applications for research on ancillary studies that aim to leverage the resources from the ongoing parent clinical studies such as well-characterized patient cohort(s), infrastructure, data, and biological samples. https://www.grants.gov/search-results-detail/359073 (R01) https://www.grants.gov/search-results-detail/359092 (R21)	Total funding of 2 million (R01) Total funding of \$600,000 (R21)	Estimated post date: 2/4/26 Estimated proposal date: 4/6/26
45.	Forecast: Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed) (NIH/NIAMS) FOR-AR-26-008	The CCCRs are expected to develop novel methods, metrics, and outcome measures to address critical clinical research needs and knowledge gaps, incorporating patient and community preferences and ensuring community representation at all research stages. https://www.grants.gov/search-results-detail/359075	TBD	Estimated post date: 5/25/26 Estimated proposal date: 9/25/26
		NIH COMMON FUND (3)		
46.	NIH Director's Pioneer Award Program (DP1 CT Optional) (NIH Common Fund) RFA-RM-25-001	This NOFO supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-25-001.html	Up to \$700,000 per year, for up to 5 years	Proposal: 9/9/25
47.	NIH Director's New Innovator Award Program (DP2 CT Optional) (NIH Common Fund) RFA-RM-25-002	This NOFO supports early stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-25-002.html	Up to \$475,000 per year, for 5 years	Proposal: 8/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NIH COMMON FUND		
48.	NIH Director's Transformative Research Awards (R01 Clinical Trial Optional) (NIH Common Fund) RFA-RM-25-003	This NOFO supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-25-003.html	Dependent upon proposal, for up to 5 years	Proposal: 9/3/25
		PEDIATRIC HEALTH (2)		
49.	Forecast: Impact of Technology and Digital Media Exposure Usage on Child and Adolescent Development (NIH/NICHHD) NOT-HD-25-008	This NOFO will solicit applications for research on the impact of technology and digital media on children and adolescents. Technology and digital media (TDM) encompasses social media, applications, websites, television, motion pictures, artificial intelligence, mobile devices, computers, video games, virtual and augmented reality, and other content, networks, or platforms disseminated through the internet, broadcasted, or other media technologies, as applicable. Collectively, they have become an integral part of our children's and families' daily lives. There is therefore an urgent need to understand how TDM use and exposure impacts children's health and development, as well as how it alters the very nature of interactions between children and their family members, peers, and society at large. https://www.grants.gov/search-results-detail/359070	Total funding of \$3 million	Estimated post date: 3/1/26 Estimated proposal date: 6/30/26
50.	Environmental influences on Child Health Outcomes (ECHO) Cohort Data and Biospecimen Access (X01 Clinical Trial Not Allowed) (NIH) PAR-25-437	This PAR provides opportunities for individuals across the scientific community to leverage non-ECHO funding to conduct ancillary studies on the ECHO Cohort Consortium's data platform, including assay of ECHO's large number of biospecimen resources. The ECHO Cohort's dataset integrates longitudinal data from more than 130,000 maternal and child participants across the U.S. The data include prenatal and child environmental exposures of many kinds, and five primary pediatric outcome areas: pre-, peri-, and postnatal outcomes; upper and lower airway outcomes; obesity and its consequences; neurodevelopment; and positive health. https://grants.nih.gov/grants/guide/pa-files/PAR-25-437.html	Resource support only (X01)	Multiple deadlines; PAR open through 3/1/28
		REGENERATIVE MEDICINE (1)		
51.	Forecast: Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) (NIH/NCATS) FOR-TR-27-002	This NOFO will support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. https://www.grants.gov/search-results-detail/359866	TBD	Estimated post date: 10/15/25 Estimated proposal date: 2/17/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (10)		
52.	SBIR and STTR: Open Topic Phase I Call for Innovative Defense-Related Dual-Purpose Technologies/Solutions with a Clear Air Force/Space Force Stakeholder Need (DoD/AF) AFX255-PCSO1 AFX255-PCSO2 AFX25E-PTCSO1 AFX25E-PTCSO2	These topics seek innovative, commercial technologies proposed to create new Air Force or Space Force solutions or potential new capabilities fulfilling requirements, closing capability gaps, or providing potential technological advancements. The topic is seeking varying technical/scientific approaches and/or varying and new technologies for transition into the DAF. Primary objectives of this topic include exploring innovative technology solutions applicable to both defense and non-defense markets, scaling capability, and growing the industrial base for defense. https://www.dodsbirsttr.mil/topics-app/	Up to \$75,000, for up to 90 days (SBIR) Up to \$110,000, for up to 90 days (STTR)	Proposal: 8/5/25
53.	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) (NIH/NCI) FOR-CA-25-086	The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. https://www.grants.gov/search-results-detail/359726	TBD	Estimated post date: 8/29/25 Estimated proposal date: 10/30/25
54.	Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed) (NIH) FOR-CA-25-087	This NOFO will support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. It has two equally important goals: entrepreneurial mentoring support, and product development support. https://www.grants.gov/search-results-detail/359724	TBD	Estimated post date: 8/29/25 Estimated proposal date: 10/30/25
55.	NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (NIH/CDC/FDA) FOR-OD-26-001	This NOFO will invite eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, Phase II, Direct to Phase II (NIH Only), Fast-Track (NIH only), and Phase IIB (NIH only) grant applications. https://www.grants.gov/search-results-detail/359671	TBD	Estimated post date: 10/1/25 Estimated proposal date: 1/5/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
56.	NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required) (NIH/CDC) FOR-OD-26-002	This NOFO will accept (SBIR) Phase I, Phase II, Direct to Phase II (NIH Only), Fast-Track (NIH only), and Phase IIB (NIH only) grant applications. Small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the awarding components are encouraged to begin to consider applying for this new NOFO. https://www.grants.gov/search-results-detail/359758	TBD	Estimated post date: 10/1/25 Estimated proposal date: 1/5/26
57.	NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) (NIH) FOR-OD-26-003	This NOFO will invite eligible United States SBCs to submit Small Business Technology Transfer (STTR) Phase I, Phase II, Fast-Track, and Phase IIB grant applications. https://www.grants.gov/search-results-detail/359757	TBD	Estimated post date: 10/1/25 Estimated proposal date: 1/5/26
58.	SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required) (NIH) FOR-OD-26-007	The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage R&D not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, IND-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. https://www.grants.gov/search-results-detail/359668	TBD	Estimated post date: 10/1/25 Estimated proposal date: 1/5/26
		SURGICAL DATA SCIENCE (1)		
59.	Polyphonic™ AI Fund for Surgery QuickFire Challenge (J&J)	Innovators around the world are invited to submit ideas for AI technologies with the potential to enhance surgical care and improve patient outcomes across the following categories: Surgical decision support; Data management & governance processes; and Surgical efficiency. Specific surgical areas of interest include: Soft tissue surgery including but not limited to colorectal, bariatric, thoracic, urology, gynecology and general surgery. https://jnjinnovation.com/innovation-challenges/Polyphonic-AI-Fund-for-Surgery-QuickFire-Challenge	Up to \$100,000	Proposal: 8/22/25
		THERAPEUTICS (2)		
60.	Forecast: Selective Precision Targeting (SPoT) (NIH/NCATS) FOR-TR-27-003	This initiative aims to determine a mechanism for precise and on-target therapeutic drug delivery to specific hard-to-reach locations within the human body using microphysiological systems. Targeted drug-delivery systems are methods for delivering medications to a specific area of the body to increase the concentration of the drug in that area. Hard-to-reach locations in the body include the blood-brain barrier, central nervous system, placenta, retina, or a tumor. https://www.grants.gov/search-results-detail/359852	Total funding of \$1.5 million	Estimated post date: 12/15/25 Estimated proposal date: 2/17/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
61.	Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) (NIH) PAR-25-442	This NOFO solicits applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes. https://grants.nih.gov/grants/guide/pa-files/PAR-25-442.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 2/17/28
		TOXIC EXPOSURES (1)		
62.	Forecast: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed) (NIH/NIAID/NIAMS) FOR-AR-26-010	This NOFO will solicit applications aimed at elucidating the pathological mechanisms underlying skin injury caused by toxic chemicals identified by DHS as high-consequence public health threats. This initiative will emphasize the understanding of commonalities in the fundamental mechanisms of skin injuries caused by vesicants such as sulfur mustard, Lewisite, nitrogen mustard, phosgene oxime, arsenicals, and other toxic chemicals. https://www.grants.gov/search-results-detail/359695	Total funding of \$2.5 million	Estimated post date: 2/5/25 Estimated proposal date: 6/5/26





Recurring Opportunities

July 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
63.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/opp/c575f73500844322be760e0d98c233ac/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
64.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/173be613d10249d8b0096c649e5203b8/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
65.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/opp/d85f2223a88442f3ba6eedf9a0629775/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
66.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/ca0ae33ab9544686b47788025c67cca2/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
67.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/90af749106d64028a0976bae4b47e25f/view https://sam.gov/opp/bc7252f0517b48d983c63265bffb82b/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
68.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The BM&P Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio-functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fad41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
69.	Research Interests of the Air Force Office of Scientific Research FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological natural by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well-understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://www.grants.gov/search-results-detail/359050	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
70.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, the Life Sciences Research Center, is intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (9)		
71.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
72.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
73.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
74.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
75.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. View the full list of research topics . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
76.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
77.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
78.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	This BAA covers many areas of scientific and technical areas of expertise, including: Soldier Protection and Survivability; Chemical/Biological Protection for Individuals; Biomechanics; Warrior Performance; Technology Assessment and Simulation Tools; Biotechnology; Physical Performance Technologies; and Medical Simulation and Training. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
79.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobe38cdob1	Dependent upon proposal	White papers accepted through 12/31/2030
80.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
81.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view	Dependent upon proposal	Proposal: 9/25/28
82.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
83.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/10/25
84.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bb0a713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26
		DEFENSE THREAT REDUCTION AGENCY (4)		
85.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
86.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
87.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
88.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034
		DEPARTMENT OF ENERGY (1)		
89.	FY 2025 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003432	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/356590	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION (2)		
90.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis through 11/5/25.
91.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to \$1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 11/5/25. Proposal: 11/5/25
		NAVY (3)		
92.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/25
93.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1ee082f371ab449294ac084bb06ba6c0/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
94.	<p>OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM)</p> <p>HQ003425BOTA1</p>	<p>OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain.</p> <p>https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view</p>	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (7)		
95.	<p>Phased Large Awards for Comparative Effectiveness Research -- Cycle 3 2025</p>	<p>This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health.</p> <p>https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-3-2025</p>	Up to \$22 million, for up to 6.5 years	<p>System opens: 8/12/25</p> <p>Letter of intent: 9/23/25</p> <p>Proposal: 1/13/26</p>
96.	<p>Broad Pragmatic Studies Funding Announcement -- Cycle 3 2025</p>	<p>This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes, based on how their proposed research aligns with the themes. Cycle 3 SAEs include: Social Isolation and Loneliness in Older Adults, Health Communication Strategies for Uptake of COVID-19 Vaccine, and Promoting Sleep Health in Inpatient Settings.</p> <p>https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-3-2025</p>	Up to \$12 million, for up to 5 years Dependent upon award mechanism	<p>System opens: 8/12/25</p> <p>Letter of intent: 9/23/25</p> <p>Proposal: 1/13/26</p>
97.	<p>Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 3 2025</p>	<p>This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research.</p> <p>https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-3-2025</p>	Up to \$1.5 million, for up to 3 years	<p>System opens: 8/12/25</p> <p>Letter of intent: 9/23/25</p> <p>Proposal: 1/13/26</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
98.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 3 2025	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-3-2025	Up to \$750,000, for up to 3 years	System opens: 8/12/25 Letter of intent: 9/23/25 Proposal: 1/13/26
99.	Engagement Award: Capacity Building -- Fall 2025 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-fall-2025-cycle	Up to \$300,000, for up to 2 years	System opens: 7/17/25 Letter of intent: 9/29/25 Proposal: 1/12/26
100.	Engagement Award: Stakeholder Convening Support -- Fall 2025 Cycle	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-fall-2025-cycle	Up to \$125,000, for up to 1 year	System opens: 7/17/25 Letter of intent: 9/29/25 Proposal: 1/12/26
101.	Engagement Award: Dissemination Initiative -- Fall 2025 Cycle	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-fall-2025-cycle	Up to \$300,000, for up to 2 years	System opens: 7/17/25 Letter of intent: 9/29/25 Proposal: 1/12/26





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

July 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://us06web.zoom.us/j/84765254229?pwd=RPahprxXLHNoN4ajs94veZ6opHcZgr.1>

Meeting ID: 847 6525 4229

Passcode: 794871

